Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2026-06-01 Merger & Acquisition
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
SC TO-C
Merger & Acquisition
2026-06-01 English
8-K
M&A Activity Classification · 85% confidence The provided document is a Form 8-K “Current Report” under the Securities Exchange Act of 1934. It falls under Item 8.01 “Other Events” and details an amendment to a merger agreement and the delay/negotiation of a tender offer for all outstanding shares of Lisata Therapeutics. This is clearly an announcement relating to an M&A transaction (tender offer and merger agreement amendment), but it is not the actual proxy or tender offer statement itself (e.g., Schedule TO or 14D-9). Therefore, it should be classified under M&A Activity, which covers announcements and documents related to merger proposals or takeover bids.
2026-06-01 English
SC TO-C
Merger & Acquisition
2026-05-29 English
8-K
M&A Activity Classification · 90% confidence The document is a U.S. SEC Form 8-K current report announcing Item 1.01 “Entry into a Material Definitive Agreement,” specifically an amendment to a previously announced Agreement and Plan of Merger. It details changes to merger consideration, the form of contingent value rights, extension of the tender offer commencement date and Outside Date, and references tender offer materials to be filed on Schedule TO and Schedule 14D-9. This is a merger-related announcement, fitting the M&A Activity category (Code: TAR).
2026-05-29 English
10-Q - LISATA THERAPEUTICS, INC. (0000320017) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
SC14D9C
Merger & Acquisition Classification · 95% confidence The document is a Schedule 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act relating to a tender offer, which is explicitly listed under Merger & Acquisition filings (Form SC 14D9, SC TO-*). Therefore, it falls into the Merger & Acquisition category.
2026-05-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.